In 68 adults who started ART in early HIV and then stopped it, two long-acting bNAbs (3BNC117-LS plus 10-1074-LS) versus placebo left 75% vs 11% free of viral rebound at 20 weeks (HR 0·09); no serious adverse events were treatment-related.
RCTn = 68
Lee et al. Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial